Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 30608991.
- Also identified by DOI 10.1371/journal.pone.0210593 and PMC identifier 6319730.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0164646.].